Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 538019, 24 pages
http://dx.doi.org/10.1155/2015/538019
Review Article

Insulin-Like Growth Factor System in Cancer: Novel Targeted Therapies

1NMR Research Centre, Indian Institute of Science, Bangalore 560012, India
2Solid State and Structural Chemistry Unit, Indian Institute of Science, Bangalore 560012, India

Received 7 July 2014; Revised 13 October 2014; Accepted 20 October 2014

Academic Editor: Eileen M. McGowan

Copyright © 2015 Varsha P. Brahmkhatri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. R. Clemmons, “Value of insulin-like growth factor system markers in the assessment of growth hormone status,” Endocrinology and Metabolism Clinics of North America, vol. 36, no. 1, pp. 109–129, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. S. M. Firth and R. C. Baxter, “Cellular actions of the insulin-like growth factor binding proteins,” Endocrine Reviews, vol. 23, no. 6, pp. 824–854, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. L. E. H. Smith, W. Shen, C. Perruzzi et al., “Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor,” Nature Medicine, vol. 5, no. 12, pp. 1390–1395, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. M. J. Horney, D. W. Shirley, D. T. Kurtz, and S. A. Rosenzweig, “Elevated glucose increases mesangial cell sensitivity to insulin-like growth factor I,” American Journal of Physiology: Renal Physiology, vol. 274, no. 6, part 2, pp. F1045–F1053, 1998. View at Google Scholar · View at Scopus
  5. M. G. Slomiany and S. A. Rosenzweig, “IGF-1-induced VEGF and IGFBP-3 secretion correlates with increased HIF-1α expression and activity in retinal pigment epithelial cell line D407,” Investigative Ophthalmology & Visual Science, vol. 45, no. 8, pp. 2838–2847, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. K. T. Flaherty, F. S. Hodi, and D. E. Fisher, “From genes to drugs: targeted strategies for melanoma,” Nature Reviews Cancer, vol. 12, no. 5, pp. 349–361, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. M. J. Higgins and J. Baselga, “Targeted therapies for breast cancer,” Journal of Clinical Investigation, vol. 121, no. 10, pp. 3797–3803, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. A. M. Scott, J. D. Wolchok, and L. J. Old, “Antibody therapy of cancer,” Nature Reviews Cancer, vol. 12, no. 4, pp. 278–287, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Chames, M. van Regenmortel, E. Weiss, and D. Baty, “Therapeutic antibodies: successes, limitations and hopes for the future,” British Journal of Pharmacology, vol. 157, no. 2, pp. 220–233, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. S. A. Rosenzweig and H. S. Atreya, “Defining the pathway to insulin-like growth factor system targeting in cancer,” Biochemical Pharmacology, vol. 80, no. 8, pp. 1115–1124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Werner, G. G. Re, I. A. Drummond et al., “Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 12, pp. 5828–5832, 1993. View at Publisher · View at Google Scholar · View at Scopus
  12. A. O. W. Stretton, “The first sequence: fred Sanger and insulin,” Genetics, vol. 162, no. 2, pp. 527–532, 2002. View at Google Scholar · View at Scopus
  13. Z. Qu, J. C. Chow, P.-R. Ling, T. R. Ziegler, B. R. Bistrian, and R. J. Smith, “Tissue-specific effects of chronic dietary protein restriction and gastrostomy on the insulin-like growth factor-I pathway in the liver and colon of adult rats,” Metabolism: Clinical and Experimental, vol. 46, no. 6, pp. 691–697, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. W. D. Salmon Jr. and W. H. Daughaday, “A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro,” The Journal of Laboratory and Clinical Medicine, vol. 49, no. 6, pp. 825–836, 1957. View at Google Scholar · View at Scopus
  15. E. Rinderknecht and R. E. Humbel, “The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin,” The Journal of Biological Chemistry, vol. 253, no. 8, pp. 2769–2776, 1978. View at Google Scholar · View at Scopus
  16. T. L. Blundell, S. Bedarkar, and R. E. Humbel, “Tertiary structures, receptor binding, and antigenicity of insulinlike growth factors,” Federation Proceedings, vol. 42, no. 9, pp. 2592–2597, 1983. View at Google Scholar · View at Scopus
  17. J. Wang, J. Zhou, and C. A. Bondy, “Igf1 promotes longitudinal bone growth by insulin-like actions augmenting chondrocyte hypertrophy,” The FASEB Journal, vol. 13, no. 14, pp. 1985–1990, 1999. View at Google Scholar · View at Scopus
  18. A. J. D'Ercole, G. T. Applewhite, and L. E. Underwood, “Evidence that somatomedin is synthesized by multiple tissues in the fetus,” Developmental Biology, vol. 75, no. 2, pp. 315–328, 1980. View at Publisher · View at Google Scholar · View at Scopus
  19. C. T. Roberts Jr., S. R. Lasky, W. L. Lowe Jr., W. T. Seaman, and D. LeRoith, “Molecular cloning of rat insulin-like growth factor I complementary deoxyribonucleic acids: differential messenger ribonucleic acid processing and regulation by growth hormone in extrahepatic tissues,” Molecular Endocrinology, vol. 1, no. 3, pp. 243–248, 1987. View at Publisher · View at Google Scholar · View at Scopus
  20. V. K. M. Han, P. K. Lund, D. C. Lee, and A. J. D'Ercole, “Expression of somatomedin/insulin-like growth factor messenger ribonucleic acids in the human fetus: identification, characterization, and tissue distribution,” The Journal of Clinical Endocrinology & Metabolism, vol. 66, no. 2, pp. 422–429, 1988. View at Publisher · View at Google Scholar · View at Scopus
  21. W. L. Lowe Jr., S. R. Lasky, D. LeRoith, and C. T. Roberts Jr., “Distribution and regulation of rat insulin-like growth factor I messenger ribonucleic acids encoding alternative carboxyterminal E-peptides: evidence for differential processing and regulation in liver,” Molecular Endocrinology, vol. 2, no. 6, pp. 528–535, 1988. View at Publisher · View at Google Scholar · View at Scopus
  22. O. G. P. Isaksson, J. O. Jansson, and I. A. M. Gause, “Growth hormone stimulates longitudinal bone growth directly,” Science, vol. 216, no. 4551, pp. 1237–1239, 1982. View at Publisher · View at Google Scholar · View at Scopus
  23. M. N. Pollak, E. S. Schernhammer, and S. E. Hankinson, “Insulin-like growth factors and neoplasia,” Nature Reviews Cancer, vol. 4, no. 7, pp. 505–518, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Wang, W. Niu, D. P. Witte et al., “Overexpression of insulin-like growth factor-binding protein-4 (IGFBP-4) in smooth muscle cells of transgenic mice through a smooth muscle α- actin-IGFBP-4 fusion gene induces smooth muscle hypoplasia,” Endocrinology, vol. 139, no. 5, pp. 2605–2614, 1998. View at Google Scholar · View at Scopus
  25. P. Ye, J. Carson, and A. J. D'Ercole, “In vivo actions of insulin-like growth factor-I (IGF-I) on brain myelination: studies of IGF-I and IGF binding protein-1 (IGFBP-1) transgenic mice,” The Journal of Neuroscience, vol. 15, no. 11, pp. 7344–7356, 1995. View at Google Scholar · View at Scopus
  26. A. J. D'Ercole, Z. Dai, Y. Xing et al., “Brain growth retardation due to the expression of human insulin like growth factor binding protein-1 in transgenic mice: an in vivo model for the analysis of igf function in the brain,” Developmental Brain Research, vol. 82, no. 1-2, pp. 213–222, 1994. View at Publisher · View at Google Scholar · View at Scopus
  27. W. Ni, K. Rajkumar, J. I. Nagy, and L. J. Murphy, “Impaired brain development and reduced astrocyte response to injury in transgenic mice expressing IGF binding protein-1,” Brain Research, vol. 769, no. 1, pp. 97–107, 1997. View at Publisher · View at Google Scholar · View at Scopus
  28. D. LeRoith, H. Werner, D. Beitner-Johnson, and C. T. Roberts Jr., “Molecular and cellular aspects of the insulin-like growth factor I receptor,” Endocrine Reviews, vol. 16, no. 2, pp. 143–163, 1995. View at Publisher · View at Google Scholar · View at Scopus
  29. C. E. H. Stewart and P. Rotwein, “Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors,” Physiological Reviews, vol. 76, no. 4, pp. 1005–1026, 1996. View at Google Scholar · View at Scopus
  30. J. I. Jones and D. R. Clemmons, “Insulin-like growth factors and their binding proteins: biological actions,” Endocrine Reviews, vol. 16, no. 1, pp. 3–34, 1995. View at Google Scholar · View at Scopus
  31. H. Yu and T. Rohan, “Role of the insulin-like growth factor family in cancer development and progression,” Journal of the National Cancer Institute, vol. 92, no. 18, pp. 1472–1489, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Sepp-Lorenzino, “Structure and function of the insulin-like growth factor I receptor,” Breast Cancer Research and Treatment, vol. 47, no. 3, pp. 235–253, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Steele-Perkins, J. Turner, J. C. Edman et al., “Expression and characterization of a functional human insulin-like growth factor I receptor,” The Journal of Biological Chemistry, vol. 263, no. 23, pp. 11486–11492, 1988. View at Google Scholar · View at Scopus
  34. A. L. Frattali and J. E. Pessin, “Relationship between α subunit ligand occupancy and β subunit autophosphorylation in insulin/insulin-like growth factor-1 hybrid receptors,” The Journal of Biological Chemistry, vol. 268, no. 10, pp. 7393–7400, 1993. View at Google Scholar · View at Scopus
  35. D. Chrysis, A. S. Calikoglu, P. Ye, and A. J. D'Ercole, “Insulin-like growth factor-I overexpression attenuates cerebellar apoptosis by altering the expression of Bcl family proteins in a developmentally specific manner,” The Journal of Neuroscience, vol. 21, no. 5, pp. 1481–1489, 2001. View at Google Scholar · View at Scopus
  36. K. D. Dentremont, P. Ye, A. J. D'Ercole, and J. R. O'Kusky, “Increased insulin-like growth factor-I (IGF-I)expression during early postnatal development differentially increases neuron number and growth in medullary nuclei of the mouse,” Developmental Brain Research, vol. 114, no. 1, pp. 135–141, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Zhao, M.-C. Monier-Faugere, M. C. Langub et al., “Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation,” Endocrinology, vol. 141, no. 7, pp. 2674–2682, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Reiss, W. Cheng, A. Ferber et al., “Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 16, pp. 8630–8635, 1996. View at Publisher · View at Google Scholar · View at Scopus
  39. M. E. Coleman, F. Demayo, R. Geske, C. Montgomery, and R. J. Schwartz, “Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice,” The Journal of Biological Chemistry, vol. 270, no. 20, pp. 12109–12116, 1995. View at Publisher · View at Google Scholar · View at Scopus
  40. A. J. Oates, L. M. Schumaker, S. B. Jenkins et al., “The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene,” Breast Cancer Research and Treatment, vol. 47, no. 3, pp. 269–281, 1998. View at Publisher · View at Google Scholar · View at Scopus
  41. D. O. Morgan, J. C. Edman, D. N. Standring et al., “Insulin-like growth factor II receptor as a multifunctional binding protein,” Nature, vol. 329, no. 6137, pp. 301–307, 1987. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Oshima, C. M. Nolan, J. W. Kyle, J. H. Grubb, and W. S. Sly, “The human cation-independent mannose 6-phosphate receptor. Cloning and sequence of the full-length cDNA and expression of functional receptor in cos cells,” The Journal of Biological Chemistry, vol. 263, no. 5, pp. 2553–2562, 1988. View at Google Scholar · View at Scopus
  43. T. Braulke, “Type-2 IGF receptor: a multi-ligand binding protein,” Hormone and Metabolic Research, vol. 31, no. 2-3, pp. 242–246, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. Yang, A. Hoeflich, O. Butenandt, and W. Kiess, “Opposite regulation of IGF-I and IGF-I receptor mRNA and concomitant changes of GH receptor and IGF-II/M6P receptor mRNA in human IM-9 lymphoblasts,” Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, vol. 1310, no. 3, pp. 317–324, 1996. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Hernández-Sánchez, H. Werner, C. T. Roberts Jr. et al., “Differential regulation of insulin-like growth factor-I (IGF-I) receptor gene expression by IGF-I and basic fibroblastic growth factor,” The Journal of Biological Chemistry, vol. 272, no. 8, pp. 4663–4670, 1997. View at Publisher · View at Google Scholar · View at Scopus
  46. S. M. Rosenthal, E. J. Brown, A. Brunetti, and I. D. Goldfine, “Fibroblast growth factor inhibits insulin-like growth factor-II (IGF-II) gene expression and increases IGF-I receptor abundance in BC3H-1 muscle cells,” Molecular Endocrinology, vol. 5, no. 5, pp. 678–684, 1991. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Rubini, H. Werner, E. Gandini, C. T. Roberts Jr., D. Leroith, and R. Baserga, “Platelet-derived growth factor increases the activity of the promoter of the insulin-like growth factor-1 (IGF-1) receptor gene,” Experimental Cell Research, vol. 211, no. 2, pp. 374–379, 1994. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Werner, “Dysregulation of the Type 1 IGF receptor as a paradigm in tumor progression,” Molecular and Cellular Endocrinology, vol. 141, no. 1-2, pp. 1–5, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. H. Werner, E. Karnieli, F. J. Rauscher III, and D. LeRoith, “Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 16, pp. 8318–8323, 1996. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Prisco, A. Hongo, M. G. Rizzo, A. Sacchi, and R. Baserga, “The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal,” Molecular and Cellular Biology, vol. 17, no. 3, pp. 1084–1092, 1997. View at Google Scholar · View at Scopus
  51. J. P. Thissen, J. M. Ketelslegers, and L. E. Underwood, “Nutritional regulation of the insulin-like growth factors,” Endocrine Reviews, vol. 15, no. 1, pp. 80–101, 1994. View at Publisher · View at Google Scholar · View at Scopus
  52. W. Zhang, W. H. Thornton Jr., and R. S. MacDonald, “Insulin-like growth factor-I and II receptor expression in rat colon mucosa are affected by dietary lipid intake,” Journal of Nutrition, vol. 128, no. 2, pp. 158–165, 1998. View at Google Scholar · View at Scopus
  53. A. Hoeflich, Y. Yang, W. Rascher et al., “Coordinate expression of insulin-like growth factor II (IGF-II) and IGP-II/mannose-6-phosphate receptor mRNA and stable expression of IGF-I receptor mRNA during differentiation of human colon carcinoma cells (Caco-2),” European Journal of Endocrinology, vol. 135, no. 1, pp. 49–59, 1996. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Takigawa, T. Okawa, H.-O. Pan et al., “Insulin-like growth factors I and II are autocrine factors in stimulating proteoglycan synthesis, a marker of differentiated chondrocytes, acting through their respective receptors on a clonal human chondrosarcoma-derived chondrocyte cell line, HCS-2/8,” Endocrinology, vol. 138, no. 10, pp. 4390–4400, 1997. View at Publisher · View at Google Scholar · View at Scopus
  55. W. Kiess, L. A. Greenstein, R. M. White, L. Lee, M. M. Rechler, and S. P. Nissley, “Type II insulin-like growth factor receptor is present in rat serum,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 21, pp. 7720–7724, 1987. View at Publisher · View at Google Scholar · View at Scopus
  56. R. G. MacDonald, M. A. Tepper, K. B. Clairmont, S. B. Perregaux, and M. P. Czech, “Serum form of the rat insulin-like growth factor II/mannose 6-phosphate receptor is truncated in the carboxyl-terminal domain,” The Journal of Biological Chemistry, vol. 264, no. 6, pp. 3256–3261, 1989. View at Google Scholar · View at Scopus
  57. K. J. Valenzano, J. Remmler, and P. Lobel, “Soluble insulin-like growth factor II/mannose 6-phosphate receptor carries multiple high molecular weight forms of insulin-like growth factor II in fetal bovine serum,” The Journal of Biological Chemistry, vol. 270, no. 27, pp. 16441–16448, 1995. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Zaina and S. Squire, “The soluble type 2 insulin-like growth factor (IGF-II) receptor reduces organ size by IGF-II-mediated and IGF-II-independent mechanisms,” The Journal of Biological Chemistry, vol. 273, no. 44, pp. 28610–28616, 1998. View at Publisher · View at Google Scholar · View at Scopus
  59. Y. Xu, A. Papageorgiou, and C. Polychronakos, “Developmental regulation of the soluble form of insulin-like growth factor-II/mannose 6-phosphate receptor in human serum and amniotic fluid,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 2, pp. 437–442, 1998. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Costello, R. C. Baxter, and C. D. Scott, “Regulation of soluble insulin-like growth factor II/mannose 6-phosphate receptor in human serum: measurement by enzyme-linked immunosorbent assay,” The Journal of Clinical Endocrinology & Metabolism, vol. 84, no. 2, pp. 611–617, 1999. View at Publisher · View at Google Scholar · View at Scopus
  61. J. Zapf, M. Waldvogel, and E. R. Froesch, “Binding of nonsuppressible insulinlike activity to human serum: evidence for a carrier protein,” Archives of Biochemistry and Biophysics, vol. 168, no. 2, pp. 638–645, 1975. View at Publisher · View at Google Scholar · View at Scopus
  62. R. L. Hintz and F. Liu, “Demonstration of specific plasma protein binding sites for somatomedin,” The Journal of Clinical Endocrinology and Metabolism, vol. 45, no. 5, pp. 988–995, 1977. View at Publisher · View at Google Scholar · View at Scopus
  63. M. M. Rechler and A. L. Brown, “Insulin-like growth factor binding proteins: gene structure and expression,” Growth Regulation, vol. 2, no. 2, pp. 55–68, 1992. View at Google Scholar · View at Scopus
  64. L. A. Bach and M. M. Rechler, “Insulin-like growth factor binding proteins,” Diabetes Reviews, vol. 3, no. 1, pp. 38–61, 1995. View at Google Scholar · View at Scopus
  65. G. M. Neumann and L. A. Bach, “The N-terminal disulfide linkages of human insulin-like growth factor-binding protein-6 (hIGFBP-6) and hIGFBP-1 are different as determined by mass spectrometry,” The Journal of Biological Chemistry, vol. 274, no. 21, pp. 14587–14594, 1999. View at Publisher · View at Google Scholar · View at Scopus
  66. R. Durai, M. Davies, W. Yang et al., “Biology of insulin-like growth factor binding protein-4 and its role in cancer (review),” International Journal of Oncology, vol. 28, no. 6, pp. 1317–1325, 2006. View at Google Scholar · View at Scopus
  67. B. Kübler, S. Cowell, J. Zapf, and T. Braulke, “Proteolysis of insulin-like growth factor binding proteins by a novel 50-kilodalton metalloproteinase in human pregnancy serum,” Endocrinology, vol. 139, no. 4, pp. 1556–1563, 1998. View at Google Scholar · View at Scopus
  68. J. C. Chen, Z. M. Shao, M. S. Sheikh et al., “Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line,” Journal of Cellular Physiology, vol. 158, no. 1, pp. 69–78, 1994. View at Publisher · View at Google Scholar · View at Scopus
  69. P. M. Yamada and K.-W. Lee, “Perspectives in mammalian IGFBP-3 biology: local vs. systemic action,” American Journal of Physiology—Cell Physiology, vol. 296, no. 5, pp. C954–C976, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. D. Romero, C. O'Neill, A. Terzic et al., “Endoglin regulates cancer-stromal cell interactions in prostate tumors,” Cancer Research, vol. 71, no. 10, pp. 3482–3493, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. R. Rajah, L. Katz, S. Nunn, P. Solberg, T. Beers, and P. Cohen, “Insulin-like growth factor binding protein (IGFBP) proteases: functional regulators of cell growth,” Cytokine and Growth Factor Reviews, vol. 6, no. 2–4, pp. 273–284, 1995. View at Google Scholar · View at Scopus
  72. M. Takaoka, H. Harada, C. D. Andl et al., “Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3,” Cancer Research, vol. 64, no. 21, pp. 7711–7723, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. J. L. Fowlkes, “Insulinlike growth factor-binding protein proteolysis: an emerging paradigm in insulinlike growth factor physiology,” Trends in Endocrinology and Metabolism, vol. 8, no. 8, pp. 299–306, 1997. View at Publisher · View at Google Scholar · View at Scopus
  74. J. L. Fowlkes, J. J. Enghild, K. Suzuki, and H. Nagase, “Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures,” Journal of Biological Chemistry, vol. 269, no. 41, pp. 25742–25746, 1994. View at Google Scholar · View at Scopus
  75. R. P. Verma and C. Hansch, “Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs,” Bioorganic & Medicinal Chemistry, vol. 15, no. 6, pp. 2223–2268, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. J. L. Fowlkes, K. M. Thrailkill, D. M. Serra, K. Suzuki, and H. Nagase, “Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases,” Cytokine and Growth Factor Reviews, vol. 6, no. 2–4, pp. 255–263, 1995. View at Google Scholar · View at Scopus
  77. H. A. Coppock, A. White, J. D. Aplin, and M. Westwood, “Matrix metalloprotease-3 and -9 proteolyze insulin-like growth factor-binding protein-1,” Biology of Reproduction, vol. 71, no. 2, pp. 438–443, 2004. View at Publisher · View at Google Scholar · View at Scopus
  78. R. Rajah, R. V. Nachajon, M. H. Collins, H. Hakonarson, M. M. Grunstein, and P. Cohen, “Elevated levels of the IGF-binding protein protease MMP-1 in asthmatic airway smooth muscle,” The American Journal of Respiratory Cell and Molecular Biology, vol. 20, no. 2, pp. 199–208, 1999. View at Publisher · View at Google Scholar · View at Scopus
  79. C. A. Conover, G. F. Faessen, K. E. Ilg et al., “Pregnancy-associated plasma protein-A is the insulin-like growth factor binding protein-4 protease secreted by human ovarian granulosa cells and is a marker of dominant follicle selection and the corpus luteum,” Endocrinology, vol. 142, no. 5, pp. 2155–2158, 2001. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Mark, B. Kübler, S. Höning et al., “Diversity of human insulin-like growth factor (IGF) binding protein-2 fragments in plasma: primary structure, IGF-binding properties, and disulfide bonding pattern,” Biochemistry, vol. 44, no. 9, pp. 3644–3652, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Zhang, E. P. Smith, H. Kuroda, W. Banach, S. D. Chernausek, and J. A. Fagin, “Targeted expression of a protease-resistant IGFBP-4 mutant in smooth muscle of transgenic mice results in IGFBP-4 stabilization and smooth muscle hypotrophy,” The Journal of Biological Chemistry, vol. 277, no. 24, pp. 21285–21290, 2002. View at Publisher · View at Google Scholar · View at Scopus
  82. L. A. Bach, P. Fu, and Z. Yang, “Insulin-like growth factor-binding protein-6 and cancer,” Clinical Science, vol. 124, no. 4, pp. 215–229, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. A. J. Ryan, S. Napoletano, P. A. Fitzpatrick, C. A. Currid, N. C. O'Sullivan, and J. H. Harmey, “Expression of a protease-resistant insulin-like growth factor-binding protein-4 inhibits tumour growth in a murine model of breast cancer,” British Journal of Cancer, vol. 101, no. 2, pp. 278–286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. C.-L. Soh, K. McNeil, C. M. Owczarek et al., “Exogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer,” British Journal of Cancer, vol. 110, no. 12, pp. 2855–2864, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. Y. Oh, S. R. Nagalla, Y. Yamanaka, H.-S. Kim, E. Wilson, and R. G. Rosenfeld, “Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7: recombinant human mac25 protein specifically binds IGF-I and -II,” The Journal of Biological Chemistry, vol. 271, no. 48, pp. 30322–30325, 1996. View at Publisher · View at Google Scholar · View at Scopus
  86. M. R. Corkins, J. A. Vanderhoof, D. H. Slentz, R. G. MacDonald, and J. H. Y. Park, “Growth stimulation by transfection of intestinal epithelial cells with an antisense insulin-like growth factor binding protein-2 construct,” Biochemical and Biophysical Research Communications, vol. 211, no. 3, pp. 707–713, 1995. View at Publisher · View at Google Scholar · View at Scopus
  87. O. M. Casey, R. Fitzpatrick, J. O. McInerney, D. G. Morris, R. Powell, and J. M. Sreenan, “Analysis of gene expression in the bovine corpus luteum through generation and characterisation of 960 ESTs,” Biochimica et Biophysica Acta: Gene Structure and Expression, vol. 1679, no. 1, pp. 10–17, 2004. View at Publisher · View at Google Scholar · View at Scopus
  88. F. Domínguez, S. Avila, A. Cervero et al., “A combined approach for gene discovery identifies insulin-like growth factor-binding protein-related protein I as a new gene implicated in human endometrial receptivity,” The Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 4, pp. 1849–1857, 2003. View at Publisher · View at Google Scholar · View at Scopus
  89. S.-A. Wandji, J. E. Gadsby, J. A. Barber, and J. M. Hammond, “Messenger ribonucleic acids for mac25 and connective tissue growth factor (CTGF) are inversely regulated during folliculogenesis and early luteogenesis,” Endocrinology, vol. 141, no. 7, pp. 2648–2657, 2000. View at Publisher · View at Google Scholar · View at Scopus
  90. C. C. Sprenger, M. E. Vail, K. Evans, J. Simurdak, and S. R. Plymate, “Over-expression of insulin-like growth factor binding protein-related protein-1(IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis,” Oncogene, vol. 21, no. 1, pp. 140–147, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. C. Rupp, M. Scherzer, A. Rudisch et al., “IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor-stroma interaction,” Oncogene, 2014. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Zhu, F. Xu, J. Zhang, W. Ruan, and M. Lai, “Insulin-like growth factor binding protein-related protein 1 and cancer,” Clinica Chimica Acta, vol. 431, pp. 23–32, 2014. View at Publisher · View at Google Scholar · View at Scopus
  93. W. Jiang, C. Xiang, S. Cazacu, C. Brodie, and T. Mikkelsen, “Insulin-like growth factor binding protein 7 mediates glioma cell growth and migration,” Neoplasia, vol. 10, no. 12, pp. 1335–1342, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. V. Evdokimova, C. E. Tognon, T. Benatar et al., “IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors,” Science Signaling, vol. 5, no. 255, article ra92, 2012. View at Publisher · View at Google Scholar · View at Scopus
  95. T. Fukushima and H. Kataoka, “Roles of insulin-like growth factor binding protein-2 (IGFBP-2) in glioblastoma,” Anticancer Research, vol. 27, no. 6, pp. 3685–3692, 2007. View at Google Scholar · View at Scopus
  96. F. E. Carrick, B. E. Forbes, and J. C. Wallace, “BIAcore analysis of bovine insulin-like growth factor (IGF)-binding protein-2 identifies major IGF binding site determinants in both the amino- and carboxyl-terminal domains,” The Journal of Biological Chemistry, vol. 276, no. 29, pp. 27120–27128, 2001. View at Publisher · View at Google Scholar · View at Scopus
  97. G. D. Hobba, A. Löthgren, E. Holmberg, B. E. Forbes, G. L. Francis, and J. C. Wallace, “Alanine screening mutagenesis establishes tyrosine 60 of bovine insulin-like growth factor binding protein-2 as a determinant of insulin-like growth factor binding,” The Journal of Biological Chemistry, vol. 273, no. 31, pp. 19691–19698, 1998. View at Publisher · View at Google Scholar · View at Scopus
  98. G. D. Hobba, B. E. Forbes, E. J. Parkinson, G. L. Francis, and J. C. Wallace, “The insulin-like growth factor (IGF) binding site of bovine insulin-like growth factor binding protein-2 (biGFBP-2) probed by iodination,” The Journal of Biological Chemistry, vol. 271, no. 48, pp. 30529–30536, 1996. View at Publisher · View at Google Scholar · View at Scopus
  99. B. E. Forbes, D. Turner, S. J. Hodge, K. A. McNeil, G. Forsberg, and J. C. Wallace, “Localization of an insulin-like growth factor (IGF) binding site of bovine IGF binding protein-2 using disulfide mapping and deletion mutation analysis of the C-terminal domain,” The Journal of Biological Chemistry, vol. 273, no. 8, pp. 4647–4652, 1998. View at Publisher · View at Google Scholar · View at Scopus
  100. M. M. Kibbey, M. J. Jameson, E. M. Eaton, and S. A. Rosenzweig, “Insulin-like growth factor binding protein-2: contributions of the C-terminal domain to insulin-like growth factor-1 binding,” Molecular Pharmacology, vol. 69, no. 3, pp. 833–845, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. F. E. Carrick, M. G. Hinds, K. A. McNeil, J. C. Wallace, B. E. Forbes, and R. S. Norton, “Interaction of insulin-like growth factor (IGF)-I and -II with IGF binding protein-2: mapping the binding surfaces by nuclear magnetic resonance,” Journal of Molecular Endocrinology, vol. 34, no. 3, pp. 685–698, 2005. View at Publisher · View at Google Scholar · View at Scopus
  102. Z. Kuang, S. Yao, K. A. McNeil et al., “Cooperativity of the N- and C-terminal domains of insulin-like growth factor (IGF) binding protein 2 in IGF binding,” Biochemistry, vol. 46, no. 48, pp. 13720–13732, 2007. View at Publisher · View at Google Scholar · View at Scopus
  103. B. E. Forbes, P. McCarthy, and R. S. Norton, “Insulin-like growth factor binding proteins: a structural perspective,” Frontiers in Endocrinology, vol. 3, article 38, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Swain, M. G. Slomiany, S. A. Rosenzweig, and H. S. Atreya, “High-yield bacterial expression and structural characterization of recombinant human insulin-like growth factor binding protein-2,” Archives of Biochemistry and Biophysics, vol. 501, no. 2, pp. 195–200, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. M. Swain, R. Thirupathi, B. Krishnarjuna et al., “Spontaneous and reversible self-assembly of a polypeptide fragment of insulin-like growth factor binding protein-2 into fluorescent nanotubular structures,” Chemical Communications, vol. 46, no. 2, pp. 216–218, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Y. Kim, J. A. Toretsky, D. Scher, and L. J. Helman, “The role of IGF-1R in pediatric malignancies,” The Oncologist, vol. 14, no. 1, pp. 83–91, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. M. M. Chitnis, J. S. P. Yuen, A. S. Protheroe, M. Pollak, and V. M. Macaulay, “The type 1 insulin-like growth factor receptor pathway,” Clinical Cancer Research, vol. 14, no. 20, pp. 6364–6370, 2008. View at Publisher · View at Google Scholar · View at Scopus
  108. K. Takeuchi and F. Ito, “Receptor tyrosine kinases and targeted cancer therapeutics,” Biological and Pharmaceutical Bulletin, vol. 34, no. 12, pp. 1774–1780, 2011. View at Publisher · View at Google Scholar · View at Scopus
  109. R. Baserga, F. Peruzzi, and K. Reiss, “The IGF-1 receptor in cancer biology,” International Journal of Cancer, vol. 107, no. 6, pp. 873–877, 2003. View at Publisher · View at Google Scholar · View at Scopus
  110. A. G. Renehan, M. Zwahlen, C. Minder, S. T. O'Dwyer, S. M. Shalet, and M. Egger, “Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis,” The Lancet, vol. 363, no. 9418, pp. 1346–1353, 2004. View at Publisher · View at Google Scholar · View at Scopus
  111. H. Cui, M. Cruz-Correa, F. M. Giardiello et al., “Loss of IGF2 imprinting: a potential marker of colorectal cancer risk,” Science, vol. 299, no. 5613, pp. 1753–1755, 2003. View at Publisher · View at Google Scholar · View at Scopus
  112. G. E. Krassas, N. Pontikides, T. Kaltsas et al., “Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease,” The Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 1, pp. 132–135, 2003. View at Publisher · View at Google Scholar · View at Scopus
  113. P. Vorwerk, H. Wex, C. Bessert, B. Hohmann, U. Schmidt, and U. Mittler, “Loss of imprinting of IGF-II gene in children with acute lymphoblastic leukemia,” Leukemia Research, vol. 27, no. 9, pp. 807–812, 2003. View at Publisher · View at Google Scholar · View at Scopus
  114. C. M. Coutinho-Camillo, M. M. Brentani, O. Butugan, H. Torloni, and M. A. Nagai, “Relaxation of imprinting of IGFII gene in juvenile nasopharyngeal angiofibromas,” Diagnostic Molecular Pathology, vol. 12, no. 1, pp. 57–62, 2003. View at Publisher · View at Google Scholar · View at Scopus
  115. O. Ogawa, D. M. Becroft, I. M. Morison et al., “Constitutional relaxation of insulin-like growth factor II gene imprinting associated with Wilms' tumour and gigantism,” Nature Genetics, vol. 5, no. 4, pp. 408–412, 1993. View at Publisher · View at Google Scholar · View at Scopus
  116. J. Zhang, J. M. Trent, and P. S. Meltzer, “Rapid isolation and characterization of amplified DNA by chromosome microdissection: Identification of IGF1R amplification in malignant melanoma,” Oncogene, vol. 8, no. 10, pp. 2827–2831, 1993. View at Google Scholar · View at Scopus
  117. G. Armengol, S. Knuutila, F. Lluís, G. Capellà, R. Miró, and M. R. Caballín, “DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic adenocarcinoma,” Cancer Genetics and Cytogenetics, vol. 116, no. 2, pp. 133–141, 2000. View at Publisher · View at Google Scholar · View at Scopus
  118. A. Almeida, M. Muleris, B. Dutrillaux, and B. Malfoy, “The insulin-like growth factor I receptor gene is the target for the 15q26 amplicon in breast cancer,” Genes Chromosomes and Cancer, vol. 11, no. 1, pp. 63–65, 1994. View at Publisher · View at Google Scholar · View at Scopus
  119. A. Belfiore, “The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer,” Current Pharmaceutical Design, vol. 13, no. 7, pp. 671–686, 2007. View at Publisher · View at Google Scholar · View at Scopus
  120. E. A. Bohula, M. P. Playford, and V. M. Macaulay, “Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment,” Anti-Cancer Drugs, vol. 14, no. 9, pp. 669–682, 2003. View at Google Scholar · View at Scopus
  121. J. S. P. Yuen and V. M. Macaulay, “Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer,” Expert Opinion on Therapeutic Targets, vol. 12, no. 5, pp. 589–603, 2008. View at Publisher · View at Google Scholar · View at Scopus
  122. E. Surmacz, “Growth factor receptors as therapeutic targets: Strategies to inhibit the insulin-like growth factor I receptor,” Oncogene, vol. 22, no. 42, pp. 6589–6597, 2003. View at Publisher · View at Google Scholar · View at Scopus
  123. I. Singh, H. Amin, B. Rah, and A. Goswami, “Targeting EGFR and IGF 1R: a promising combination therapy for metastatic cancer,” Frontiers in Bioscience—Scholar, vol. 5, no. 1, pp. 231–246, 2013. View at Google Scholar · View at Scopus
  124. L. Mohanraj and Y. Oh, “Targeting IGF-I, IGFBPs and IGF-I receptor system in cancer: the current and future in breast cancer therapy,” Recent Patents on Anti-Cancer Drug Discovery, vol. 6, no. 2, pp. 166–177, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. J. Riedemann and V. M. Macaulay, “IGF1R signalling and its inhibition,” Endocrine-Related Cancer, vol. 13, no. 1, pp. S33–S43, 2006. View at Publisher · View at Google Scholar · View at Scopus
  126. M. Pollak, “The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology,” Clinical Cancer Research, vol. 18, no. 1, pp. 40–50, 2012. View at Publisher · View at Google Scholar · View at Scopus
  127. F. I. Arnaldez and L. J. Helman, “Targeting the insulin growth factor receptor 1,” Hematology/Oncology Clinics of North America, vol. 26, no. 3, pp. 527–542, 2012. View at Publisher · View at Google Scholar · View at Scopus
  128. A. Arcaro, “Targeting the insulin-like growth factor-1 receptor in human cancer,” Frontiers in Pharmacology, vol. 4, article 30, 2013. View at Publisher · View at Google Scholar · View at Scopus
  129. D. Yee, “Insulin-like growth factor receptor inhibitors: baby or the bathwater?” Journal of the National Cancer Institute, vol. 104, no. 13, pp. 975–981, 2012. View at Publisher · View at Google Scholar · View at Scopus
  130. V. M. Macaulay, “The IGF receptor as anticancer treatment target,” Novartis Foundation Symposium, vol. 262, pp. 235–246, 2004. View at Publisher · View at Google Scholar · View at Scopus
  131. Y. Adachi, C. T. Lee, and D. P. Carbone, “Genetic blockade of the insulin-like growth factor 1 receptor for human malignancy,” Novartis Foundation Symposium, vol. 262, pp. 177–268, 2004. View at Google Scholar
  132. Y. Adachi, C. Lee, K. Coffee et al., “Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines,” Gastroenterology, vol. 123, no. 4, pp. 1191–1204, 2002. View at Publisher · View at Google Scholar · View at Scopus
  133. C. Liu, Z. Zhang, H. Tang, Z. Jiang, L. You, and Y. Liao, “Crosstalk between IGF-1R and other Tumor Promoting Pathways,” Current Pharmaceutical Design, vol. 20, no. 17, pp. 2912–2921, 2014. View at Publisher · View at Google Scholar
  134. M. Xue, X. Cao, Y. Zhong et al., “Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives,” Current Pharmaceutical Design, vol. 18, no. 20, pp. 2901–2913, 2012. View at Publisher · View at Google Scholar · View at Scopus
  135. J. van der Veeken, S. Oliveira, R. M. Schiffelers, G. Storm, P. M. P. Van Bergen En Henegouwen, and R. C. Roovers, “Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: Implications for cancer therapy,” Current Cancer Drug Targets, vol. 9, no. 6, pp. 748–760, 2009. View at Publisher · View at Google Scholar · View at Scopus
  136. M. Mancini, M. B. Gariboldi, E. Taiana et al., “Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells,” British Journal of Cancer, vol. 110, no. 12, pp. 2865–2873, 2014. View at Publisher · View at Google Scholar · View at Scopus
  137. A. T. de Souza, G. R. Hankins, M. K. Washington, T. C. Orton, and R. L. Jirtle, “M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity,” Nature Genetics, vol. 11, no. 4, pp. 447–449, 1995. View at Publisher · View at Google Scholar · View at Scopus
  138. Y. Myal, R. P. C. Shiu, B. Bhaumick, and M. Bala, “Receptor binding and growth-promoting activity of insulin-like growth factors in human breast cancer cells (T-47D) in culture,” Cancer Research, vol. 44, no. 12, part 1, pp. 5486–5490, 1984. View at Google Scholar · View at Scopus
  139. S. E. Hankinson, W. C. Willett, G. A. Colditz et al., “Circulating concentrations of insulin-like growth factor-I and risk of breast cancer,” The Lancet, vol. 351, no. 9113, pp. 1393–1396, 1998. View at Publisher · View at Google Scholar · View at Scopus
  140. H. Yu, M. R. Spitz, J. Mistry, J. Gu, W. K. Hong, and X. Wu, “Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis,” Journal of the National Cancer Institute, vol. 91, no. 2, pp. 151–156, 1999. View at Publisher · View at Google Scholar · View at Scopus
  141. J. Ma, M. N. Pollak, E. Giovannucci et al., “Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3,” Journal of the National Cancer Institute, vol. 91, no. 7, pp. 620–625, 1999. View at Publisher · View at Google Scholar · View at Scopus
  142. R. Shi, H. J. Berkel, and H. Yu, “Insulin-like growth factor-I and prostate cancer: a meta-analysis,” British Journal of Cancer, vol. 85, no. 7, pp. 991–996, 2001. View at Publisher · View at Google Scholar · View at Scopus
  143. J. M. Chan, M. J. Stampfer, E. Giovannucci et al., “Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study,” Science, vol. 279, no. 5350, pp. 563–566, 1998. View at Publisher · View at Google Scholar · View at Scopus
  144. Y. Wu, K. Cui, K. Miyoshi et al., “Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors,” Cancer Research, vol. 63, no. 15, pp. 4384–4388, 2003. View at Google Scholar · View at Scopus
  145. N. Majeed, M.-J. Blouin, P. J. Kaplan-Lefko et al., “A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model,” Oncogene, vol. 24, no. 29, pp. 4736–4740, 2005. View at Publisher · View at Google Scholar · View at Scopus
  146. M. Pollak, “Insulin, insulin-like growth factors and neoplasia,” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 22, no. 4, pp. 625–638, 2008. View at Publisher · View at Google Scholar · View at Scopus
  147. J. Gao, J. W. Chesebrough, S. A. Cartlidge et al., “Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth,” Cancer Research, vol. 71, no. 3, pp. 1029–1040, 2011. View at Publisher · View at Google Scholar · View at Scopus
  148. G. T. Tindall, S. S. Ambrose, J. H. Christy, and J. M. Patton, “Hypophysectomy in the treatment of disseminated carcinoma of the breast and prostate gland,” Southern Medical Journal, vol. 69, no. 5, pp. 579–587, 1976. View at Publisher · View at Google Scholar · View at Scopus
  149. A. Grimberg, “p53 and IGFBP-3: apoptosis and cancer protection,” Molecular Genetics and Metabolism, vol. 70, no. 2, pp. 85–98, 2000. View at Publisher · View at Google Scholar · View at Scopus
  150. M. J. Moreno, M. Ball, M. Rukhlova et al., “IGFBP-4 anti-angiogenic and anti-tumorigenic effects are associated with anti-cathepsin B activity,” Neoplasia, vol. 15, no. 5, pp. 554–567, 2013. View at Publisher · View at Google Scholar · View at Scopus
  151. A. Grimberg and P. Cohen, “Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis,” Journal of Cellular Physiology, vol. 183, no. 1, pp. 1–9, 2000. View at Google Scholar
  152. T. Nickerson, H. Miyake, M. E. Gleave, and M. Pollak, “Castration-induced apoptosis of androgen-dependent Shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins,” Cancer Research, vol. 59, no. 14, pp. 3392–3395, 1999. View at Google Scholar · View at Scopus
  153. T. Nickerson and M. Pollak, “Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins,” Urology, vol. 54, no. 6, pp. 1120–1125, 1999. View at Publisher · View at Google Scholar · View at Scopus
  154. R. C. Baxter, “IGF binding proteins in cancer: mechanistic and clinical insights,” Nature Reviews Cancer, vol. 14, no. 5, pp. 329–341, 2014. View at Publisher · View at Google Scholar · View at Scopus
  155. J. I. Jones, A. Joseph D'Ercole, C. Camacho-Hubner, and D. R. Clemmons, “Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo: effects on affinity for IGF-I,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 17, pp. 7481–7485, 1991. View at Publisher · View at Google Scholar · View at Scopus
  156. J. I. Leu, M. A. S. Crissey, and R. Taub, “Massive hepatic apoptosis associated with TGF-β1 activation after Fas ligand treatment of IGF binding protein-1-deficient mice,” The Journal of Clinical Investigation, vol. 111, no. 1, pp. 129–139, 2003. View at Publisher · View at Google Scholar · View at Scopus
  157. D. Yee, J. G. Jackson, T. W. Kozelsky, and J. A. Figueroa, “Insulin-like growth factor binding protein 1 expression inhibits insulin-like growth factor I action in MCF-7 breast cancer cells,” Cell Growth & Differentiation, vol. 5, no. 1, pp. 73–77, 1994. View at Google Scholar · View at Scopus
  158. D. Diehl, E. Hessel, D. Oesterle et al., “IGFBP-2 overexpression reduces the appearance of dysplastic aberrant crypt foci and inhibits growth of adenomas in chemically induced colorectal carcinogenesis,” International Journal of Cancer, vol. 124, no. 9, pp. 2220–2225, 2009. View at Publisher · View at Google Scholar · View at Scopus
  159. A. Hoeflich, R. Reisinger, H. Lahm et al., “Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter?” Cancer Research, vol. 61, no. 24, pp. 8601–8610, 2001. View at Google Scholar · View at Scopus
  160. V. C. Russo, B. S. Schütt, E. Andaloro et al., “Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion,” Endocrinology, vol. 146, no. 10, pp. 4445–4455, 2005. View at Publisher · View at Google Scholar · View at Scopus
  161. S. W. Song, G. N. Fuller, A. Khan et al., “IIp45, an insulin-like growth factor binding protein 2 (IGFBP-2) binding protein, antagonizes IGFBP-2 stimulation of glioma cell invasion,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 2, pp. 13970–13975, 2003. View at Publisher · View at Google Scholar · View at Scopus
  162. G. K. Wang, L. Hu, G. N. Fuller, and W. Zhang, “An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin α5 is essential for IGFBP2-induced cell mobility,” The Journal of Biological Chemistry, vol. 281, no. 20, pp. 14085–14091, 2006. View at Publisher · View at Google Scholar · View at Scopus
  163. J. S. M. de Mellow and R. C. Baxter, “Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I-stimulated DNA synthesis in human skin fibroblasts,” Biochemical and Biophysical Research Communications, vol. 156, no. 1, pp. 199–204, 1988. View at Publisher · View at Google Scholar · View at Scopus
  164. W. F. Blum, E. W. Jenne, F. Reppin, K. Kietzmann, M. B. Ranke, and J. R. Bierich, “Insulin-like growth factor I (IGF-I)-binding protein complex is a better mitogen than free IGF-I,” Endocrinology, vol. 125, no. 2, pp. 766–772, 1989. View at Publisher · View at Google Scholar · View at Scopus
  165. J. L. Martin, M. Z. Lin, E. M. McGowan, and R. C. Baxter, “Potentiation of growth factor signaling by insulin-like growth factor-binding protein-3 in breast epithelial cells requires sphingosine kinase activity,” The Journal of Biological Chemistry, vol. 284, no. 38, pp. 25542–25552, 2009. View at Publisher · View at Google Scholar · View at Scopus
  166. S. Y. Heazlewood, R. J. Neaves, B. Williams, D. N. Haylock, T. E. Adams, and S. K. Nilsson, “Megakaryocytes co-localise with hemopoietic stem cells and release cytokines that up-regulate stem cell proliferation,” Stem Cell Research, vol. 11, no. 2, pp. 782–792, 2013. View at Publisher · View at Google Scholar · View at Scopus
  167. C. A. Conover, “Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3: studies of underlying mechanism,” Endocrinology, vol. 130, no. 6, pp. 3191–3199, 1992. View at Publisher · View at Google Scholar · View at Scopus
  168. W.-Y. Kim, M.-J. Kim, H. Moon et al., “Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development,” Endocrinology, vol. 152, no. 6, pp. 2164–2173, 2011. View at Publisher · View at Google Scholar · View at Scopus
  169. B. Bartling, A. Koch, A. Simm, R. Scheubel, R. E. Silber, and A. N. Santos, “Insulin-like growth factor binding proteins-2 and -4 enhance the migration of human CD34-/CD133+ hematopoietic stem and progenitor cells,” International Journal of Molecular Medicine, vol. 25, no. 1, pp. 89–96, 2010. View at Google Scholar
  170. R. A. Mosig, M. Lobl, E. Senturk et al., “IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer,” Journal of Ovarian Research, vol. 5, no. 1, article 3, 2012. View at Publisher · View at Google Scholar · View at Scopus
  171. A. J. Butt, K. A. Dickson, F. McDougall, and R. C. Baxter, “Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo,” The Journal of Biological Chemistry, vol. 278, no. 32, pp. 29676–29685, 2003. View at Publisher · View at Google Scholar · View at Scopus
  172. B. Tanno, V. Cesi, R. Vitali et al., “Silencing of endogenous IGFBP-5 by micro RNA interference affects proliferation, apoptosis and differentiation of neuroblastoma cells,” Cell Death and Differentiation, vol. 12, no. 3, pp. 213–223, 2005. View at Publisher · View at Google Scholar · View at Scopus
  173. C. McCaig, C. M. Perks, and J. M. P. Holly, “Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin,” Journal of Cell Science, vol. 115, no. 22, pp. 4293–4303, 2002. View at Publisher · View at Google Scholar · View at Scopus
  174. S. K. Johnson and R. S. Haun, “Insulin-like growth factor binding protein-5 influences pancreatic cancer cell growth,” World Journal of Gastroenterology, vol. 15, no. 27, pp. 3355–3366, 2009. View at Publisher · View at Google Scholar · View at Scopus
  175. X. L. Xu, T. C. Lee, N. Offor et al., “Tumor-associated retinal astrocytes promote retinoblastoma cell proliferation through production of IGFBP-5,” The American Journal of Pathology, vol. 177, no. 1, pp. 424–435, 2010. View at Publisher · View at Google Scholar · View at Scopus
  176. A. Sokolović, M. Sokolović, W. Boers, R. P. O. Elferink, and P. J. Bosma, “Insulin-like growth factor binding protein 5 enhances survival of LX2 human hepatic stellate cells,” Fibrogenesis and Tissue Repair, vol. 3, article 3, 2010. View at Publisher · View at Google Scholar · View at Scopus
  177. L. J. Cobb, D. A. M. Salih, I. Gonzalez et al., “Partitioning of IGFBP-5 actions in myogenesis: IGF-independent anti-apoptotic function,” Journal of Cell Science, vol. 117, part 9, pp. 1737–1746, 2004. View at Publisher · View at Google Scholar · View at Scopus
  178. H. Miyake, M. Pollak, and M. E. Gleave, “Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models,” Cancer Research, vol. 60, no. 11, pp. 3058–3064, 2000. View at Google Scholar · View at Scopus
  179. P. Fu, J. A. Thompson, and L. A. Bach, “Promotion of cancer cell migration: An insulin-like growth factor (IGF)-independent action of IGF-binding protein-6,” Journal of Biological Chemistry, vol. 282, no. 31, pp. 22298–22306, 2007. View at Publisher · View at Google Scholar · View at Scopus
  180. P. Fu, Z. Yang, and L. A. Bach, “Prohibitin-2 binding modulates insulin-like growth factor-binding protein-6 (IGFBP-6)-induced rhabdomyosarcoma cell migration,” The Journal of Biological Chemistry, vol. 288, no. 41, pp. 29890–29900, 2013. View at Publisher · View at Google Scholar · View at Scopus
  181. P. Ye, Y. Xing, Z. Dai, and A. J. D'Ercole, “In vivo actions of insulin-like growth factor-I (IGF-I) on cerebellum development in transgenic mice: evidence that IGF-I increases proliferation of granule cell progenitors,” Developmental Brain Research, vol. 95, no. 1, pp. 44–54, 1996. View at Publisher · View at Google Scholar · View at Scopus
  182. P. Ye and J. D'Ercole, “Insulin-like growth factor I (IGF-I) regulates IGF binding protein-5 gene expression in the brain,” Endocrinology, vol. 139, no. 1, pp. 65–71, 1998. View at Google Scholar
  183. J. Wang, W. Niu, Y. Nikiforov et al., “Targeted overexpression of IGF-I evokes distinct patterns of organ remodeling in smooth muscle cell tissue beds of transgenic mice,” The Journal of Clinical Investigation, vol. 100, no. 6, pp. 1425–1439, 1997. View at Publisher · View at Google Scholar · View at Scopus
  184. G. Zhao, R. L. Sutliff, C. S. Weber et al., “Smooth muscle-targeted overexpression of insulin-like growth factor I results in enhanced vascular contractility,” Endocrinology, vol. 142, no. 2, pp. 623–632, 2001. View at Publisher · View at Google Scholar · View at Scopus
  185. B. Zhu, G. Zhao, D. P. Witte, D. Y. Hui, and J. A. Fagin, “Targeted overexpression of IGF-I in smooth muscle cells of transgenic mice enhances neointimal formation through increased proliferation and cell migration after intraarterial injury,” Endocrinology, vol. 142, no. 8, pp. 3598–3606, 2001. View at Publisher · View at Google Scholar · View at Scopus
  186. M. K. Dyck, A. F. Parlow, J.-F. Sénéchal, M.-A. Sirard, and F. Pothier, “Ovarian expression of human insulin-like growth factor-I in transgenic mice results in cyst formation,” Molecular Reproduction and Development, vol. 59, no. 2, pp. 178–185, 2001. View at Publisher · View at Google Scholar · View at Scopus
  187. J. DiGiovanni, K. Kiguchi, A. Frijhoff et al., “Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 7, pp. 3455–3460, 2000. View at Publisher · View at Google Scholar · View at Scopus
  188. S. Clément, S. Refetoff, B. Robaye, J. E. Dumont, and S. Schurmans, “Low TSH requirement and goiter in transgenic mice overexpressing IGF-I and IGF-I receptor in the thyroid gland,” Endocrinology, vol. 142, no. 12, pp. 5131–5139, 2001. View at Publisher · View at Google Scholar · View at Scopus
  189. L.-T. Busund, E. Richardsen, R. Busund et al., “Significant expression of IGFBP2 in breast cancer compared with benign lesions,” Journal of Clinical Pathology, vol. 58, no. 4, pp. 361–366, 2005. View at Publisher · View at Google Scholar · View at Scopus
  190. M. L. Neuhouser, E. A. Platz, C. Till et al., “Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial,” Cancer Prevention Research, vol. 6, no. 2, pp. 91–99, 2013. View at Publisher · View at Google Scholar · View at Scopus
  191. A. J. Butt, S. M. Firth, M. A. King, and R. C. Baxter, “Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells,” The Journal of Biological Chemistry, vol. 275, no. 50, pp. 39174–39181, 2000. View at Publisher · View at Google Scholar · View at Scopus
  192. N. Miyakoshi, X. Qin, Y. Kasukawa et al., “Systemic administration of insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) increases bone formation parameters in mice by increasing IGF bioavailability via an IGFBP-4 protease-dependent mechanism,” Endocrinology, vol. 142, no. 6, pp. 2641–2648, 2001. View at Publisher · View at Google Scholar · View at Scopus
  193. A. Parker, A. Gockerman, W. H. Busby, and D. R. Clemmons, “Properties of an insulin-like growth factor-binding protein-4 protease that is secreted by smooth muscle cells,” Endocrinology, vol. 136, no. 6, pp. 2470–2476, 1995. View at Google Scholar · View at Scopus
  194. M. Iwashita, Y. Kudo, and Y. Takeda, “Effect of follicle stimulating hormone and insulin-like growth factors on proteolysis of insulin-like growth factor binding protein-4 in human granulosa cells,” Molecular Human Reproduction, vol. 4, no. 4, pp. 401–405, 1998. View at Publisher · View at Google Scholar · View at Scopus
  195. S. Mazerbourg, M. T. Overgaard, C. Oxvig et al., “Pregnancy-associated plasma protein-A (PAPP-A) in ovine, bovine, porcine, and equine ovarian follicles: involvement in IGF binding protein-4 proteolytic degradation and mRNA expression during follicular development,” Endocrinology, vol. 142, no. 12, pp. 5243–5253, 2001. View at Publisher · View at Google Scholar · View at Scopus
  196. S. Swami, N. Raghavachari, U. R. Muller, Y. P. Bao, and D. Feldman, “Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray,” Breast Cancer Research and Treatment, vol. 80, no. 1, pp. 49–62, 2003. View at Publisher · View at Google Scholar · View at Scopus
  197. H. Huynh, X. F. Yang, and M. Pollak, “A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780,” Cell Growth and Differentiation, vol. 7, no. 11, pp. 1501–1506, 1996. View at Google Scholar · View at Scopus
  198. L. A. Bach, “IGFBP-6 five years on; not so “forgotten”?” Growth Hormone and IGF Research, vol. 15, no. 3, pp. 185–192, 2005. View at Publisher · View at Google Scholar · View at Scopus
  199. L. A. Bach, “Insulin-like growth factor binding protein-6: the “forgotten” binding protein?” Hormone and Metabolic Research, vol. 31, no. 2-3, pp. 226–234, 1999. View at Publisher · View at Google Scholar · View at Scopus
  200. P. Jean Ho and R. C. Baxter, “Characterization of truncated insulin-like growth factor-binding protein-2 in human milk,” Endocrinology, vol. 138, no. 9, pp. 3811–3818, 1997. View at Publisher · View at Google Scholar · View at Scopus
  201. S. Réhault, P. Monget, S. Mazerbourg et al., “Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3,” European Journal of Biochemistry, vol. 268, no. 10, pp. 2960–2968, 2001. View at Publisher · View at Google Scholar · View at Scopus
  202. S. Miyamoto, M. Nakamura, K. Yano et al., “Matrix metalloproteinase-7 triggers the matricrine action of insulin-like growth factor-II via proteinase activity on insulin-like growth factor binding protein 2 in the extracellular matrix,” Cancer Science, vol. 98, no. 5, pp. 685–691, 2007. View at Publisher · View at Google Scholar · View at Scopus
  203. P. Monget, S. Mazerbourg, T. Delpuech et al., “Pregnancy-associated plasma protein-A is involved in insulin-like growth factor binding protein-2 (IGFBP-2) proteolytic degradation in bovine and porcine preovulatory follicles: identification of cleavage site and characterization of IGFBP-2 degradation,” Biology of Reproduction, vol. 68, no. 1, pp. 77–86, 2003. View at Publisher · View at Google Scholar · View at Scopus
  204. U. Berg, P. Bang, and C. Carlsson-Skwirut, “Calpain proteolysis of insulin-like growth factor binding protein (IGFBP) -2 and -3, but not of IGFBP-1,” Biological Chemistry, vol. 388, no. 8, pp. 859–863, 2007. View at Publisher · View at Google Scholar · View at Scopus
  205. B. A. Booth, M. Boes, and R. S. Bar, “IGFBP-3 proteolysis by plasmin, thrombin, serum: heparin binding, IGF binding, and structure of fragments,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 271, no. 3, pp. E465–E470, 1996. View at Google Scholar · View at Scopus
  206. C. Lalou, S. Sawamura, B. Segovia, Y. Ogawa, and M. Binoux, “Proteolytic fragments of insulin-like growth factor binding protein-3: N-terminal sequences and relationships between structure and biological activity,” Comptes Rendus de l'Academie des Sciences—Serie III, vol. 320, no. 8, pp. 621–628, 1997. View at Publisher · View at Google Scholar · View at Scopus
  207. E. Okabe, J.-I. Kajihara, Y. Usami, and K. Hirano, “The cleavage site specificity of human prostate specific antigen for insulin-like growth factor binding protein-3,” FEBS Letters, vol. 447, no. 1, pp. 87–90, 1999. View at Publisher · View at Google Scholar · View at Scopus
  208. H. Salahifar, S. M. Firth, R. C. Baxter, and J. L. Martin, “Characterization of an amino-terminal fragment of insulin-like growth factor binding protein-3 and its effects in MCF-7 breast cancer cells,” Growth Hormone and IGF Research, vol. 10, no. 6, pp. 367–377, 2000. View at Publisher · View at Google Scholar · View at Scopus
  209. S. D. Chernausek, C. E. Smith, K. L. Duffin, W. H. Busby, G. Wright, and D. R. Clemmons, “Proteolytic cleavage of insulin-like growth factor binding protein 4 (IGFBP-4). Localization of cleavage site to non-homologous region of native IGFBP-4,” The Journal of Biological Chemistry, vol. 270, no. 19, pp. 11377–11382, 1995. View at Publisher · View at Google Scholar · View at Scopus
  210. C. Rees, D. R. Clemmons, G. D. Horvitz, J. B. Clarke, and W. H. Busby, “A protease-resistant form of insulin-like growth factor (IGF) binding protein 4 inhibits IGF-1 actions,” Endocrinology, vol. 139, no. 10, pp. 4182–4188, 1998. View at Google Scholar · View at Scopus
  211. C. A. Conover, S. K. Durham, J. Zapf, F. R. Masiarz, and M. C. Kiefer, “Cleavage analysis of insulin-like growth factor (IGF)-dependent IGF-binding protein-4 proteolysis and expression of protease-resistant IGF-binding protein-4 mutants,” Journal of Biological Chemistry, vol. 270, no. 9, pp. 4395–4400, 1995. View at Publisher · View at Google Scholar · View at Scopus
  212. J. B. Lawrence, C. Oxvig, M. T. Overgaard et al., “The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 6, pp. 3149–3153, 1999. View at Publisher · View at Google Scholar · View at Scopus
  213. Y. Imai, W. H. Busby Jr., C. E. Smith et al., “Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture,” Journal of Clinical Investigation, vol. 100, no. 10, pp. 2596–2605, 1997. View at Publisher · View at Google Scholar · View at Scopus
  214. M. T. Overgaard, H. B. Boldt, L. S. Laursen, L. Sottrup-Jensen, C. A. Conover, and C. Oxvig, “Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase,” The Journal of Biological Chemistry, vol. 276, no. 24, pp. 21849–21853, 2001. View at Google Scholar
  215. B. Zheng, J. B. Clarke, W. H. Busby, C. Duan, and D. R. Clemmons, “Insulin-like growth factor-binding protein-5 is cleaved by physiological concentrations of thrombin,” Endocrinology, vol. 139, no. 4, pp. 1708–1714, 1998. View at Google Scholar · View at Scopus
  216. C. García-Echeverría, M. A. Pearson, A. Marti et al., “In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase,” Cancer Cell, vol. 5, no. 3, pp. 231–239, 2004. View at Publisher · View at Google Scholar · View at Scopus
  217. S. Wolf, J. Lorenz, J. Mössner, and M. Wiedmann, “Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance,” World Journal of Gastroenterology, vol. 16, no. 2, pp. 156–166, 2010. View at Publisher · View at Google Scholar · View at Scopus
  218. A. Girnita, L. Girnita, F. Del Prete, A. Bartolazzi, O. Larsson, and M. Axelson, “Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth,” Cancer Research, vol. 64, no. 1, pp. 236–242, 2004. View at Publisher · View at Google Scholar · View at Scopus
  219. D. Vasilcanu, A. Girnita, L. Girnita, R. Vasilcanu, M. Axelson, and O. Larsson, “The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway,” Oncogene, vol. 23, no. 47, pp. 7854–7862, 2004. View at Publisher · View at Google Scholar · View at Scopus
  220. R. Vasilcanu, D. Vasilcanu, L. Rosengren et al., “Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and β-arrestin1,” Oncogene, vol. 27, no. 11, pp. 1629–1638, 2008. View at Publisher · View at Google Scholar · View at Scopus
  221. E. Menu, H. Jernberg-Wiklund, H. de Raeve et al., “Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival,” International Journal of Cancer, vol. 121, no. 8, pp. 1857–1861, 2007. View at Publisher · View at Google Scholar · View at Scopus
  222. M. A. Economou, S. Andersson, D. Vasilcanu et al., “Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma,” Investigative Ophthalmology and Visual Science, vol. 49, no. 6, pp. 2337–2342, 2008. View at Publisher · View at Google Scholar · View at Scopus
  223. J. Rodon, V. DeSantos, R. J. Ferry Jr., and R. Kurzrock, “Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials,” Molecular Cancer Therapeutics, vol. 7, no. 9, pp. 2575–2588, 2008. View at Publisher · View at Google Scholar · View at Scopus
  224. J. A. Toretsky, S. M. Steinberg, M. Thakar et al., “Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors,” Cancer, vol. 92, no. 11, pp. 2941–2947, 2001. View at Google Scholar
  225. A. P. Majumdar, S. Banerjee, J. Nautiyal et al., “Curcumin synergizes with resveratrol to inhibit colon cancer,” Nutrition and Cancer, vol. 61, no. 4, pp. 544–553, 2009. View at Publisher · View at Google Scholar · View at Scopus
  226. Y. Li and T. Zhang, “Targeting cancer stem cells by curcumin and clinical applications,” Cancer Letters, vol. 346, no. 2, pp. 197–205, 2014. View at Publisher · View at Google Scholar
  227. M. A. Babcook and S. Gupta, “Apigenin: a promising anticancer agent for the modulation of the Insulin-like Growth Factor (IGF) axis in prostate cancer,” Biomedical Research, vol. 23, supplement 1, pp. 55–68, 2012. View at Google Scholar
  228. M. Jung, S. Y. Bu, K.-H. Tak, J.-E. Park, and E. Kim, “Anticarcinogenic effect of quercetin by inhibition of insulin-like growth factor (IGF)-1 signaling in mouse skin cancer,” Nutrition Research and Practice, vol. 7, no. 6, pp. 439–445, 2013. View at Publisher · View at Google Scholar · View at Scopus
  229. X. Li, Y. Feng, J. Liu, X. Feng, K. Zhou, and X. Tang, “Epigallocatechin-3-gallate inhibits IGF-I-stimulated lung cancer angiogenesis through downregulation of HIF-1alpha and VEGF expression,” Journal of Nutrigenetics and Nutrigenomics, vol. 6, no. 3, pp. 169–178, 2013. View at Publisher · View at Google Scholar · View at Scopus
  230. D. Chen and Q. P. Dou, “Tea polyphenols and their roles in cancer prevention and chemotherapy,” International Journal of Molecular Sciences, vol. 9, no. 7, pp. 1196–1206, 2008. View at Publisher · View at Google Scholar · View at Scopus
  231. S. Mondal, S. Bandyopadhyay, M. K. Ghosh, S. Mukhopadhyay, S. Roy, and C. Mandal, “Natural products: promising resources for cancer drug discovery,” Anti-Cancer Agents in Medicinal Chemistry, vol. 12, no. 1, pp. 49–75, 2012. View at Publisher · View at Google Scholar · View at Scopus
  232. N. Sultana, “Clinically useful anticancer, antitumor, and antiwrinkle agent, ursolic acid and related derivatives as medicinally important natural product,” Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 26, no. 5, pp. 616–642, 2011. View at Publisher · View at Google Scholar · View at Scopus
  233. Y.-J. Surh, “Cancer chemoprevention with dietary phytochemicals,” Nature Reviews Cancer, vol. 3, no. 10, pp. 768–780, 2003. View at Publisher · View at Google Scholar · View at Scopus
  234. N. Khan, N. Hadi, F. Afaq, D. N. Syed, M.-H. Kweon, and H. Mukhtar, “Pomegranate fruit extract inhibits prosurvival pathways in human A549 lung carcinoma cells and tumor growth in athymic nude mice,” Carcinogenesis, vol. 28, no. 1, pp. 163–173, 2007. View at Publisher · View at Google Scholar · View at Scopus
  235. C. A. Lamartiniere, M. S. Cotroneo, W. A. Fritz, J. Wang, R. Mentor-Marcel, and A. Elgavish, “Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate,” The Journal of Nutrition, vol. 132, no. 3, pp. 552s–558s, 2002. View at Google Scholar · View at Scopus
  236. Y. Li and F. H. Sarkar, “Gene expression profiles of genistein-treated PC3 prostate cancer cells,” The Journal of Nutrition, vol. 132, no. 12, pp. 3623–3631, 2002. View at Google Scholar · View at Scopus
  237. S. R. Chinni, Y. Li, S. Upadhyay, P. K. Koppolu, and F. H. Sarkar, “Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells,” Oncogene, vol. 20, no. 23, pp. 2927–2936, 2001. View at Publisher · View at Google Scholar · View at Scopus
  238. Y. Li, X. Li, and F. H. Sarkar, “Gene expression profiles of 13C- and DIM-treated PC3 human prostate cancer cells determined by cDNA microarray analysis,” Journal of Nutrition, vol. 133, no. 4, pp. 1011–1019, 2003. View at Google Scholar · View at Scopus
  239. K. Hastak, S. Gupta, N. Ahmad, M. K. Agarwal, M. L. Agarwal, and H. Mukhtar, “Role of p53 and NF-κB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells,” Oncogene, vol. 22, no. 31, pp. 4851–4859, 2003. View at Publisher · View at Google Scholar · View at Scopus